Evolent Health considers Genetic Testing for Inherited Colorectal Cancers medically necessary for the following indications:

1. **Hereditary nonpolyposis colorectal cancer (HNPCC) testing** is covered if the member meets one of the following:
   
   A. Member meets Amsterdam II criteria or revised Bethesda guidelines; or
   B. Member is diagnosed with endometrial cancer before age 50 years; or
   C. Member has a 1st- or 2nd-degree relative with a disease confirmed to be caused by a HNPCC mutation upon testing of the 1st- or 2nd-degree relative
   D. Individuals with >5 percent chance of a MMR gene mutation by prediction models

2. **Microsatellite instability (MSI) testing or immunohistochemical (IHC) analysis of the tumor (colorectal and/or endometrial)** is considered medically necessary if the member meets the following:
   - MSI is used as an initial test in persons with colorectal cancer who meet the revised Bethesda criteria in order to identify those persons who should proceed with HNPCC mutation analysis.

3. **APC testing** is considered medically necessary if the member meets the following:
   - Personal history of ≥ 20 adenomas
   - Known deleterious APC mutation in family
   - Consider testing if a personal history of a desmoid tumor, hepatoblastoma, cribriform-morular variant of papillary thyroid cancer, or between 10-20 adenomas

4. **Familial Adenomatous Polyposis (FAP) testing**: Genetic Testing to determine the carrier status of the APC gene in individuals with existing polyps is considered medically necessary in any of the following:
   - Members with greater than 100 colonic polyps identified by colonoscopy; or
   - History of FAP in first degree relatives; or
   - Individuals with 10-100 adenomas may be considered for APC testing.
5. **MYH Associated Polyposis (MAP) testing** is considered medically necessary when the member meets one of the following:

   - Individuals with personal history of adenomatous polyposis (>10 adenomas) and negative APC test and a negative family history for adenomatous polyposis; or
   - Individual with a personal history of APC and family history for recessive inheritance where only siblings are affected; or
   - Asymptomatic siblings of individuals with known MYH polyposis.

**Limitations**

1. Not indicated for mass screening of the general population.
2. In general – not recommended for individuals under the age of 18 years.
3. The test is considered experimental/investigational for all other indications
4. A member with a negative MSI-H test would not need genetic testing for HNPCC.
5. MSH6 mutations are not considered medically necessary in persons who have mutations in the MLH1 or MLH2 genes.
6. Single site MSH6 testing may be done for testing family members or persons with HNPCC from an identified MSH6 mutation.
7. All other genetic tests for inherited predisposition to colorectal cancers, other than the ones listed in this policy, are considered experimental/investigational.

**Background**

Up to one third of colorectal cancer cases are inherited. Inherited syndromes of colon cancer include:
- Familial Adenomatous Polyposis (FAP)
- MYH associated polyposis (MAP)
- Hereditary Nonpolyposis Colorectal Cancer (HNPCC) or Lynch Syndrome

FAP is an autosomal dominant syndrome caused by a germ-line mutation of the APC gene and CRC is inevitable in patients with FAP if colectomy is not performed. FAP can be identified by the appearance of characteristic polyps, the identification of HNPCC is based primarily on family history and related criteria.

Centers for Medicare and Medicaid Services (CMS) reports that HNPCC or Lynch Syndrome is an autosomal dominant syndrome that accounts for about 3-5% of colorectal cancer cases. HNPCC syndrome mutations occur in the following genes: hMLH1, hMSH2, hMSH6, PMS2 and EPCAM.

MAP arises from mutations of the MYH gene and is an autosomal recessive disease.

**Amsterdam Criteria II**
There should be at least three relatives with an HNPCC-associated cancer (cancer of the colorectum, endometrium, small bowel, ureter, or renal pelvis) and:

- One should be a first-degree relative to the other two;
- At least two successive generations should be affected;
- At least one should be diagnosed before age 50;
- Familial adenomatous polyposis should be excluded;
- Tumors should be verified by pathological examination

**Revised Bethesda Guidelines:**

- Individual with CRC diagnosed by age 50
- Individual with synchronous or metachronous CRC, or other HNPCC-associated tumors regardless of age
- Individual with CRC and MSI-H histology diagnosed by age 60
- Individual with CRC and more than 1 FDR with an HNPCC-associated tumor, with one cancer diagnosed by age 50
- Individual with CRC and more than 2 FDRs or SDRs with an HNPCC-associated tumor, regardless of age

**Codes:**

<table>
<thead>
<tr>
<th>CPT Codes / HCPCS Codes / ICD-10 Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td><strong>CPT codes:</strong></td>
</tr>
<tr>
<td>81292</td>
</tr>
<tr>
<td>81293</td>
</tr>
<tr>
<td>81294</td>
</tr>
<tr>
<td>81295</td>
</tr>
<tr>
<td>81296</td>
</tr>
</tbody>
</table>
Genetic Testing - Inherited Colorectal Cancers

Policy Number: MP-042
Last Review Date: 05/09/2019
Effective Date: 07/01/2019

<table>
<thead>
<tr>
<th>Code</th>
<th>Type and Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81297</td>
<td>MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants</td>
</tr>
<tr>
<td>81298</td>
<td>MSH6 (mutS homolog 6 [E coli]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis</td>
</tr>
<tr>
<td>81299</td>
<td>MSH6 (mutS homolog 6 [E coli]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants</td>
</tr>
<tr>
<td>81300</td>
<td>MSH6 (mutS homolog 6 [E coli]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants</td>
</tr>
<tr>
<td>81301</td>
<td>Microsatellite instability analysis (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair deficiency (e.g., BAT25, BAT26), includes comparison of neoplastic and normal tissue, if performed</td>
</tr>
<tr>
<td>81317</td>
<td>PMS2 (postmeiotic segregation increased 2 [S cerevisiae]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis</td>
</tr>
<tr>
<td>81318</td>
<td>PMS2 (postmeiotic segregation increased 2 [S cerevisiae]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis, known familial variants</td>
</tr>
<tr>
<td>81319</td>
<td>PMS2 (postmeiotic segregation increased 2 [S cerevisiae]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis, duplication/deletion variants</td>
</tr>
</tbody>
</table>

References


12. Gruber SB. New Concepts in Gastroenterology. New developments in Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) and mismatch repair


Disclaimer:
Evolent Health medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Evolent Health and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Evolent Health reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.